NeuroSense Therapeutics
modulated and levels showing target engagement | NeuroSense Therapeutics
Company
Deck Type
Sector
Industry
Deck date
October 2024
Slide
19 of 27
Related slides by other companies
Nuvalent
Investor Presentation
January 2024
of met all desired clinical characteristics phase favorable tolerability was observed in preliminary profile presented patients enrolled across six dose levels as may was not reached no clinically significant exposure response relationships for safety and efficacy were observed wide therapeutic window was consistent with selective sparing design the dose level daily maintained steady state plasma levels above target efficacy thresholds i a a a a a a target target wild type target periphery target wild type periphery data as for patients treated by data for cohort are not shown due to immaturity central nervous system hours once daily standard deviation based on tumor regression in in models bearing and respectively values for a and divided by predicted human brain to plasma ratio respectively source data on file a i | Nuvalent
Nuvalent
Investor Presentation
February 2024
of met all desired clinical characteristics phase favorable tolerability was observed in preliminary profile presented patients enrolled across six dose levels as may was not reached no clinically significant exposure response relationships for safety and efficacy were observed wide therapeutic window was consistent with selective sparing design the dose level daily maintained steady state plasma levels above target efficacy thresholds i a a a a a a target target wild type target periphery target wild type periphery data as for patients treated by data for cohort are not shown due to immaturity central nervous system standard deviation hours once daily in models in and respectively based on tumor reg on source data on file a i values for a and divided by predicted human brain to plasma ratio respectively | Nuvalent
Nuvalent
Investor Presentation
April 2024
of met all desired clinical characteristics phase favorable tolerability was observed in preliminary profile presented patients enrolled across six dose levels as may was not reached no clinically significant exposure response relationships for safety and efficacy were observed wide therapeutic window was consistent with selective sparing design the dose level daily maintained steady state plasma levels above target efficacy thresholds i a a i i a i a a a a go me nes me yes target target wild type target periphery target wild type periphery data as for patients treated by data for cohort are not shown due to immaturity centra based hours once daily standard deviation on in in models and respectively values for a and divided by predicted human brain to plasma ratio respectively on file a source | Nuvalent
Nuvalent
Investor Presentation
January 2024
of met all desired clinical characteristics phase favorable tolerability was observed in preliminary profile presented patients enrolled across six dose levels as may was not reached no clinically significant exposure response relationships for safety and efficacy were observed wide therapeutic window was consistent with selective sparing design the dose level daily maintained steady state plasma levels above target efficacy thresholds i a a a a a a target target wild type target periphery target wild type periphery data as for patients treated by data for cohort are not shown due to immaturity central nervous system hours once daily standard deviation based on tumor regression in in models bearing and respectively values for a and divided by predicted human brain to plasma ratio respectively source data on file a i | Nuvalent
Other recent decks by NeuroSense Therapeutics
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
December 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights